Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and...
73 insider purchases on record · latest filing 2026-06-05.
Insiders have also filed 15 sale transactions at ALDX.